Navigation Links
Cheap Drug Helps Smokers Quit, Study Finds
Date:9/29/2011

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Sept. 28 (HealthDay News) -- For people trying to quit smoking, the drug cytisine works better than a placebo, and its comparatively low cost makes it an appealing alternative to newer stop-smoking medications, researchers say.

Over the course of a year, researchers found cytisine, a nicotine substitute, more effective than a placebo in helping smokers stop the habit, and the researchers said its affordability could be an advantage in poorer countries.

"Many smokers can stop without help, but many are addicted and will continue until they die unless they get help," said lead researcher Robert West, from the Health Behaviour Research Center at University College London in England.

"The key feature of this drug is that it is extremely cheap and so affordable by just about anyone in the world who can afford to smoke," he added.

Cytisine, sold as Tabex in former socialist economy countries for four decades, has now been shown to be an effective and safe way of helping smokers quit, West added. But it does not have U.S. Food and Drug Administration approval, so it is not available in the United States.

The drug is extracted from the Cytisus laborinum L. (Golden Rain acacia) plant, and as a smoking-cessation aid it is similar to nicotine replacement drugs such as Chantix, patches and gums.

In Poland, where the study was done, cytisine costs $15 for a course of treatment, the researchers noted. In China, an 8-week course of nicotine-replacement therapy costs $230; an 8-week course of Zyban (bupropion) costs $123 and a 12-week course of Chantix (vareniclene) costs $327, while a pack of cigarettes typically costs 73 cents and sometimes much less, they said.

"Cytisine could save many thousands of lives, particularly in low- and middle-income countries," West said. "But it could also save health care systems and insurers in high-income countries millions on their drugs bill."

About 5 million people globally die prematurely from smoking each year, the study authors noted.

The study, published in the Sept. 29 issue of the New England Journal of Medicine, was largely paid for by Britain's publicly funded National Prevention Research Initiative.

For the study, West's team randomly assigned 740 smokers to cytisine or a placebo for 25 days. In addition, the participants received minimal counseling to help them quit. More than 80 percent of participants had already tried to quit.

After one year, 8.4 percent of those who had taken cytisine were still not smoking, compared with 2.4 percent of those who received the placebo, the researchers found.

Adverse side effects occurred more often in those receiving cytisine and included stomach ache, dry mouth, difficulty breathing and nausea. But, these were generally mild and not long lasting, the authors noted.

Commenting on the study, Dr. Michael C. Fiore, a professor of medicine and director of the Center for Tobacco Research and Intervention at the University of Wisconsin School of Medicine and Public Health in Madison, said that "the findings are encouraging and promising, but need to be replicated."

Around the world there are about one billion smokers, Fiore said. "Many of them want to quit, but don't have access to the counseling we know would help, and many of the medicines are too expensive for them to purchase," he said.

"If there is a medication that is safe, effective and inexpensive, it would be an important advance," he added. However, the results of this study need to be replicated in other groups to ensure that it is both safe and effective before cytisine can be considered such a drug, he said.

Another expert, Dr. Steven Schroeder, director of the Smoking Cessation Leadership Center at the University of California, San Francisco, added that "if cytisine comes on the market in the U.S. and it's cheap, that's great."

Schroeder said if people in a trial of cytisine were to receive as much counseling as they do in trials of other drugs, such as Zyban and Chantix, and if treatment was longer, then similar quit rates of 15 to 25 percent would be seen.

"I think you would see better results," he said.

More information

For more information on quitting smoking, visit SmokeFree.gov.

SOURCES: Robert West, Ph.D., Health Behaviour Research Center, University College London, England; Michael C. Fiore, M.D., M.P.H., professor of medicine, director, Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison; Steven Schroeder, M.D., director, Smoking Cessation Leadership Center, University of California, San Francisco; Sept. 29, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Foam injections for varicose veins better for patients and cheaper, study finds
2. Cheap drugs could save thousands of lives - in Sweden alone
3. Cheaper DNA Sequencing Coming Closer
4. Identification of fingerprint of rare tumor leads to development of cheap and reliable new test
5. Self-powered, blood-activated sensor detects pancreatitis quickly and cheaply
6. Cheaper, Older Treatment for Vasculitis Beats Out New Drug
7. Many HIV-Infected Kids Could Use Cheaper Treatment Safely
8. Mathematical models for breast cancer detection with microwave tomography are cheaper and less risky
9. Simpler and cheaper antibiotic prophylaxis with insertion of nutrition catheter in the stomach
10. New pathway to cheap insulin
11. Launching New Cloud Server Technologies on Website Hosting and Much Cheaper Web Hosting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cheap Drug Helps Smokers Quit, Study Finds
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
(Date:12/8/2016)... WV (PRWEB) , ... December 08, 2016 , ... ... it will become Quality Insights beginning January 1, 2017. The name change ... its commitment to measuring and improving health care quality. , “We are very ...
(Date:12/8/2016)... ... 08, 2016 , ... ZyDoc , a New York-based ... Data Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” ... comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
(Date:12/8/2016)... Australia Glaucoma Surgery Devices Market Outlook ... "Australia Glaucoma Surgery Devices Market Outlook to 2022", ... Surgery Devices market. The report provides value, in ... average prices (USD) within market segement - Glaucoma ... shares and distribution shares data for each of ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
Breaking Medicine Technology: